3D1-MMAE / XYone Therapeutics - LARVOL DELTA

Development of a highly efficacious, first-in-class antibody-drug conjugate against a novel MUC1-C oncoprotein for metastatic colorectal cancer. (ASCO 2024) - "The results demonstrate that treatment of diverse mCRC cell lines, SW620, SK-CO-1 and HCT116/MUC1 with 3D1-MMAE or 7B8-MMAE is associated with substantial killing with low nM IC50... MUC1-C-ADC has demonstrated a favorable toxicity profile and potent anti-tumor activities in the mCRC. Together, these results suggest advancing the anti-MUC1-C-MMAE ADCs as a novel therapeutic for mCRC."

Metastases • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • MUC1

Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment. (ASCO 2024) - "Anti-MUC1 antibody-drug conjugates (ADCs) were generated by coupling monomethyl auristatin E (3D1-MMAE, 7B8-MMAE) via V-C-PAB linker and characterized for anti-tumor activity against pancreatic cancer cells including MIA PaCa-1, CAPAN2 and HAPF-II... Targeted delivery of MMAE toxin to the pancreatic cancer cells presents an exciting opportunity for a novel therapeutic intervention for the treatment of pancreatic cancer patients with MUC1 over expression in tumors."

Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • MUC1